In Q1 2026, Foresite Capital held 8 positions worth $237.1M. They initiated 1 new position and exited 7. Their largest holding was PHVS ($135.0M). Portfolio value grew +15.6% versus the prior quarter.
Frequently asked questions
What stocks did Foresite Capital own in Q1 2026?
Foresite Capital held 8 biotech stocks in their 13F portfolio in Q1 2026. Their top positions include PHVS, CYTK, EIKN, LYEL, RLAY. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Foresite Capital's portfolio worth in Q1 2026?
Foresite Capital's tracked biotech portfolio was worth $237.1M across 8 positions, with total assets under management of approximately $4B. Portfolio values are based on 13F filings with the SEC.
What did Foresite Capital buy in Q1 2026?
Foresite Capital initiated 1 new position in Q1 2026, including EIKN. They also increased 2 existing positions.
What did Foresite Capital sell in Q1 2026?
Foresite Capital fully exited 7 positions in Q1 2026, including NTRA, KURA, SNDX, CBAY, QSIAW and 2 more. They also trimmed 1 existing positions.
Is Foresite Capital a biotech fund?
Data science-driven healthcare crossover fund investing from late-stage private through public equity. Uses proprietary data analytics and clinical expertise to identify asymmetric risk/reward opportunities across biotech and life sciences.
Want AI analysis, insider signals, and catalyst overlays for Foresite Capital?
View latest Foresite Capitalportfolio →